NEW

GE Healthcare Invests $50M in Wisconsin Facility

GE Healthcare has announced a $50 million investment in its existing West Milwaukee facility as part of its intention (proposal only; final decision to be made after required bargaining with relevant unions) to concentrate teams and resources in key facilities across...

New Version of c.cam Cardiac SPECT System Debuts in U.S.

Siemens Healthineers has introduced a new version of its c.cam dedicated cardiac nuclear medicine system to the U.S. market. This single-photon emission computed tomography (SPECT) scanner with a reclining patient chair offers nuclear cardiology providers a low total...

Physicians Highlight Potential of Radiopharmaceuticals in Oncology

The Medical Imaging & Technology Alliance (MITA), along with the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR) and the Society of Nuclear Medicine & Molecular Imaging (SNMMI), hosted a virtual briefing for Capitol Hill staff this month with...

Nanox Signs Agreement to Deploy 630 Units in Mexico

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that it has entered into an exclusive distribution agreement with SPI Medical (SPI) for the deployment and introduction of Nanox’s medical imaging services in Mexico. SPI Medical, S. A. P....

ProbeHunter Granted Patent

The ProbeHunter system that validates the performance of ultrasound probes in real time has been granted a patent for the invention in the USA and Sweden.

“As patent holder it is with great humility that we receive this recognition,” ProbeHunter CEO Björn Segall said. “It is of importance for patient safety to test and quality assure ultrasound probes on a frequent basis. Studies show that up to 40% of the probes need to be attended to at a hospital that have not tested the probes. After yearly testing it is possible to arrive on a faulty frequency of 10-15%. Due to the fact that even some new probes can have some kind of inaccuracy or damage.”

“It has been noted in many cases that the doctors and biotechs are not aware of the problem, since the problem often occurs in the non-imaging modes like CW-doppler or Elastography. The problem is that you cannot see the problem, that’s the problem. You need to test,” he added.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *